Alternative Splicing and Leukemia Initiating Cells (ASLIC)

Civil Hospices of Lyon

Status: Unknown

Conditions: Acute Myeloid Leukemia

Treatments: Other: Assessment of splicing variants

Study type: Observational

Funder types: Other

Identifiers

NCT03156933

69HCL16_0800

Details and patient eligibility

About

Aberrant RNA splicing and mutations in spliceosome complex in acute myeloid leukaemia (AML) are frequent. It have been shown that some splicing variants had a prognostic value in AML.

AML are characterized by their propensity to relapse because of the persistence of leukaemia initiating cells (LICs).

The aim of this study is to determine the splice variants on AML initiator cells and define a splicing pattern.

Enrollment: 500 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age ≥ 18 years-old
• Patients treated at the south lyon hospital center
• Patients with a diagnosis of acute myeloid leukemia confirmed in cytology and whose involvement of the 11q23 locus was confirmed by in situ hybridization
• Patients for whom a sample is available in the cytogenetic laboratory of the south lyon hospital center

Exclusion criteria

None

Trial design

500 participants in 1 patient group

Splicing variants

Description:

Sample of acute myeloid leukaemia primary cells

Treatment:

Other: Assessment of splicing variants